China approves Huahui Health's Libevitug injection for treating hepatitis D; first of its kind; NMPA grants conditional approval.
On January 27, 2026, Huahui Health revealed that the China National Medical Products Administration (NMPA) has provided conditional approval for its Libevitug injection to address chronic hepatitis D virus infection in adults, with or without compensated cirrhosis.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments